- Conditions
- Diabetic Retinopathy
- Interventions
- Fenofibrate, Placebo
- Drug · Other
- Lead sponsor
- Jaeb Center for Health Research
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 563 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 66
- States / cities
- Glendale, California • Huntington Beach, California • Loma Linda, California + 55 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 673–696
of 7,623
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Brain and Central Nervous System Tumors, Neuroblastoma, Sarcoma
- Interventions
- vinorelbine tartrate
- Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 21 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2007
- U.S. locations
- 200
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 149 more
- Conditions
- Systemic Lupus Erythematosus (With and Without Nephritis), Idiopathic Inflammatory Myopathy, Systemic Sclerosis
- Interventions
- ALLO-329, Cyclophosphamide, Fludarabine
- Genetic · Drug
- Lead sponsor
- Allogene Therapeutics
- Industry
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 16
- States / cities
- Phoenix, Arizona • Loma Linda, California • Aurora, Colorado + 13 more
- Conditions
- Gastroesophageal Reflux
- Interventions
- pantoprazole sodium enteric-coated spheroid
- Drug
- Lead sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 1 Year to 5 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 36
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Oakland, California + 32 more
- Conditions
- Obesity
- Interventions
- survodutide, Placebo
- Combination Product
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 726 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 32
- States / cities
- Phoenix, Arizona • Spring Valley, California • Walnut Creek, California + 29 more
- Conditions
- Lung Diseases, Interstitial
- Interventions
- Nintedanib, Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 663 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 52
- States / cities
- Birmingham, Alabama • Los Angeles, California • Sacramento, California + 40 more
- Conditions
- Metastatic Fallopian Tube Carcinoma, Metastatic Ovarian Carcinoma, Metastatic Primary Peritoneal Carcinoma, Ovarian Endometrioid Tumor, Ovarian High Grade Serous Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Primary Peritoneal Cancer AJCC v7
- Interventions
- Berzosertib, Carboplatin, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Aurora, Colorado + 11 more
- Conditions
- Low Grade Astrocytoma, Low Grade Glioma, Metastatic Low Grade Astrocytoma, Metastatic Low Grade Glioma, WHO Grade 1 Glioma, WHO Grade 2 Glioma
- Interventions
- Biospecimen Collection, Carboplatin, Echocardiography Test, Magnetic Resonance Imaging, Questionnaire Administration, Selumetinib Sulfate, Vincristine Sulfate
- Procedure · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 2 Years to 21 Years
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2030
- U.S. locations
- 124
- States / cities
- Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 101 more
- Conditions
- Heart Failure, Decompensated Heart Failure, Acute Heart Failure
- Interventions
- CXL-1427, Placebo
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 14
- States / cities
- Gainesville, Florida • Jacksonville, Florida • Macon, Georgia + 10 more
- Conditions
- Relapsed/Refractory Multiple Myeloma
- Interventions
- AMG 701, Pomalidomide, Dexamethasone
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 174 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 17
- States / cities
- Scottsdale, Arizona • Little Rock, Arkansas • Jacksonville, Florida + 12 more
- Conditions
- HIV Infections, Meningitis
- Interventions
- Quadrivalent meningococcal conjugate vaccine
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 2 Years to 24 Years
- Enrollment
- 384 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 35
- States / cities
- Alhambra, California • Long Beach, California • Los Angeles, California + 25 more
- Conditions
- Small Cell Lung Cancer, Non-small Cell Lung Cancer, Squamous, Non-small Cell Lung Cancer, Non-squamous, Head and Neck Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Prostate Cancer, Melanoma
- Interventions
- ladiratuzumab vedotin, pembrolizumab
- Drug
- Lead sponsor
- Seagen Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 205 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 27
- States / cities
- Chandler, Arizona • Los Angeles, California • Santa Rosa, California + 24 more
- Conditions
- Breast Neoplasms
- Interventions
- Chemotherapy
- Drug
- Lead sponsor
- QLT Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2003
- U.S. locations
- 4
- States / cities
- Jacksonville, Florida • Vincennes, Indiana • Arlington, Texas + 1 more
- Conditions
- Opioid-Related Disorders, Drug Addiction, Pregnancy Related, Substance Abuse, Drug Abuse, Neonatal Abstinence Syndrome, Neonatal Opiate Withdrawal Syndrome, Drug Abuse in Pregnancy
- Interventions
- Buprenorphine Injection, Buprenorphine Sublingual Product
- Drug
- Lead sponsor
- T. John Winhusen, PhD
- Other
- Eligibility
- Not listed
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 10
- States / cities
- Jacksonville, Florida • Boston, Massachusetts • Portland, Oregon + 6 more
- Conditions
- Clostridium Difficile Infection
- Interventions
- C. difficile Toxoid Vaccine, Placebo: 0.9% normal saline
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 9,302 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2018
- U.S. locations
- 142
- States / cities
- Huntsville, Alabama • Mobile, Alabama • Flagstaff, Arizona + 124 more
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Decitabine and Cedazuridine (ASTX727), Venetoclax
- Drug
- Lead sponsor
- Taiho Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 24
- States / cities
- Los Angeles, California • Palo Alto, California • New Haven, Connecticut + 20 more
- Conditions
- Neuroblastoma
- Interventions
- filgrastim, sargramostim, carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, conventional surgery, neoadjuvant therapy
- Biological · Drug · Procedure
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 20 Years
- Enrollment
- 573 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1988 – 2011
- U.S. locations
- 207
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more
- Conditions
- Visual Acuity
- Interventions
- JJVC Fitting Guides
- Device
- Lead sponsor
- Johnson & Johnson Vision Care, Inc.
- Industry
- Eligibility
- 40 Years to 70 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Proliferative Glomerulonephritis With Monoclonal IgG Deposits
- Interventions
- Daratumumab
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 4
- States / cities
- Jacksonville, Florida • Rochester, Minnesota • Chapel Hill, North Carolina + 1 more
- Conditions
- Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Recurrent WHO Grade 2 Glioma, Refractory Ependymoma, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma, Refractory WHO Grade 2 Glioma, Wilms Tumor
- Interventions
- Ivosidenib
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Months to 21 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 171
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 129 more
- Conditions
- Acute Heart Failure
- Interventions
- RLX030, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 6,600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 105
- States / cities
- Huntsville, Alabama • Montgomery, Alabama • Tucson, Arizona + 76 more
- Conditions
- Advanced Colorectal Cancer, Metastatic Colorectal Cancer
- Interventions
- MRTX849, Cetuximab, mFOLFOX6 Regimen, FOLFIRI Regimen
- Drug · Biological
- Lead sponsor
- Mirati Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 461 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 185
- States / cities
- Alabaster, Alabama • Bessemer, Alabama • Birmingham, Alabama + 122 more
- Conditions
- Low Back Pain
- Interventions
- Oxycodone/Naloxone Controlled-release, Placebo
- Drug
- Lead sponsor
- Purdue Pharma LP
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,095 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 151
- States / cities
- Birmingham, Alabama • Haleyville, Alabama • Huntsville, Alabama + 123 more
- Conditions
- Depressive Disorder, Major
- Interventions
- Rapastinel, Placebo
- Drug
- Lead sponsor
- Naurex, Inc, an affiliate of Allergan plc
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 465 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 31
- States / cities
- Beverly Hills, California • Costa Mesa, California • Encino, California + 28 more